A Phase Iia, Multicenter, Treatment Assigned, Open-label, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Vanutide cridificar (Primary) ; QS 21
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 17 Sep 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 21 Jan 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record..